Drugdocs | Zerbaxa

An independent source of information on U.S. brand name drugs for health professionals

An independent source of information on U.S. brand name drugs for health professionals

Zerbaxa

Chemical Name	ceftolozane/tazobactam
Dosage Form	Injection (intravenous; ceftolozane/tazobactam (1 g/0.5 g))
Drug Class	Inhibitors
System	Urinary
Company	Merck & Co.
Approval Year	2014

Indication

For the treatment of the following infections caused by designated susceptible microorganisms: 1. Complicated Intra-abdominal Infections, used in combination with metronidazole. 2. Complicated Urinary Tract Infections, including Pyelonephritis.

Last updated on 4/19/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document Title	Year	Source
Zerbaxa (ceftolozane/tazobactam) Prescribing Information	2014	Cubist Pharmaceuticals U.S., Lexington, MA

Document Title	Year	Source
Ceftolozane and tazobactam for the treatment of bacterial infections: a review of clinical effectiveness, cost-effectiveness, and guidelines.	2016	CADTH

Document Title	Year	Source
The use of ceftolozane-tazobactam in the treatment of complicated intra-abdominal infections and complicated urinary tract infections—A meta-analysis of randomized controlled trials.	2020	International Journal of Antimicrobial Agents
Clinical cure rate and cost-effectiveness of carbapenem-sparing beta-lactams vs. meropenem for Gram-negative infections: A systematic review, meta-analysis, and cost-effectiveness analysis.	2020	International Journal of Antimicrobial Agents